{"id":"pseudomonas-aeruginosa","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"1-5%","effect":"Allergic reactions"},{"rate":"rare","effect":"Seizures"}]},"_chembl":null,"_dailymed":{"setId":"0ccc9d9a-58d4-4957-91a3-4e8c04d1c86d","title":"B-FORCE (ECHINACEA ANGUSTIFOLIA, LOMATIUM DISSECTUM, MYRRHA, NASTURTIUM AQUATICUM, TABEBUIA IMPETIGINOSA, HYDRASTIS CANADENSIS, PROPOLIS, GLANDULA SUPRARENALIS SUIS, LYMPH NODE (SUIS), SPLEEN (SUIS), THYMUS (SUIS), THYROIDINUM (SUIS), ARSENICUM ALBUM, BELLADONNA, HYPERICUM PERFORATUM, PHOSPHORUS, BOTULINUM, COLIBACILLINUM CUM NATRUM MURIATICUM, PROTEUS (VULGARIS), PSEUDOMONAS AERUGINOSA, PROTEUS (MORGANI), SALMONELLA TYPHI NOSODE, CLOSTRIDIUM PERFRINGENS) LIQUID [BIOACTIVE NUTRITIONAL, INC.]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pseudomonas aeruginosa is a bacterium that can cause a variety of infections, and this antibiotic works by inhibiting the enzyme responsible for peptidoglycan synthesis in the bacterial cell wall, ultimately leading to cell lysis and death.","oneSentence":"Pseudomonas aeruginosa is a broad-spectrum antibiotic that targets bacterial cell wall synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:06:43.328Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pneumonia"},{"name":"Urinary tract infections"},{"name":"Skin and soft tissue infections"}]},"trialDetails":[{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT06870409","phase":"PHASE3","title":"Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis","status":"RECRUITING","sponsor":"University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)","startDate":"2025-02-05","conditions":"Endocarditis, Bacterial","enrollment":30},{"nctId":"NCT07469436","phase":"","title":"mexB Efflux Pump Gene Expression, Activity and Biofilm Formation in Clinical Isolates of Pseudomonas Aeruginosa","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04","conditions":"Pseudomonas Aeroginosa","enrollment":80},{"nctId":"NCT06080698","phase":"NA","title":"Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-02-22","conditions":"Gram-negative Bacteremia","enrollment":1030},{"nctId":"NCT07088926","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-06","conditions":"Bronchiectasis With Pseudomonas Aeruginosa Colonization","enrollment":435},{"nctId":"NCT06663176","phase":"PHASE1, PHASE2","title":"Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thirty Respiratory Limited","startDate":"2024-10-16","conditions":"Non-Cystic Fibrosis Bronchiectasis","enrollment":60},{"nctId":"NCT07460297","phase":"NA","title":"Pseudomonas Aeruginosa Injection Combined With Polyvinylpyrrolidone-Iodine in Immediate Breast Reconstruction Surgery With Implants","status":"ENROLLING_BY_INVITATION","sponsor":"Jianyi Li","startDate":"2025-04-16","conditions":"Postoperative Seroma Rate, Drainage Tube Removal Time, and Capsular Contracture Rate, Seroma Following Procedure","enrollment":100},{"nctId":"NCT05282082","phase":"","title":"Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-03-01","conditions":"Pseudomonas Aeruginosa, Colonization, Asymptomatic, Nosocomial Infection","enrollment":2105},{"nctId":"NCT03947957","phase":"NA","title":"Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Brest","startDate":"2020-10-02","conditions":"Cystic Fibrosis","enrollment":70},{"nctId":"NCT06507605","phase":"PHASE1","title":"Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-08-30","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":240},{"nctId":"NCT03969901","phase":"PHASE2, PHASE3","title":"Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-10-08","conditions":"Suspected or Documented Gram-negative Bacterial Infection","enrollment":115},{"nctId":"NCT06772090","phase":"NA","title":"Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-12-25","conditions":"Solid Tumor, Adult, Cytotoxicity","enrollment":40},{"nctId":"NCT06822465","phase":"","title":"Pathobiomes in Gut of Critically Ill Patients","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-12-19","conditions":"Pseudomonas Aeruginosa","enrollment":100},{"nctId":"NCT07382271","phase":"NA","title":"Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-02","conditions":"Urinary Tract Infections, Urinary Tract Infections Caused by Drug-resistant Bacteria","enrollment":6},{"nctId":"NCT05210439","phase":"PHASE4","title":"Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2022-04-28","conditions":"Bloodstream Infection","enrollment":306},{"nctId":"NCT04673175","phase":"PHASE4","title":"Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-01-10","conditions":"Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection","enrollment":17},{"nctId":"NCT05731427","phase":"","title":"Research on the Mechanism Affecting Progression of Bronchiectasis","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-02-01","conditions":"Bronchiectasis","enrollment":150},{"nctId":"NCT05616221","phase":"PHASE2","title":"Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection","status":"COMPLETED","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"2023-01-10","conditions":"Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection","enrollment":48},{"nctId":"NCT05079620","phase":"PHASE4","title":"Early Antibiotics After Aspiration in ICU Patients","status":"TERMINATED","sponsor":"UConn Health","startDate":"2021-11-30","conditions":"Aspiration, Aspiration Pneumonia","enrollment":5},{"nctId":"NCT06016088","phase":"PHASE1, PHASE2","title":"A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection","status":"RECRUITING","sponsor":"Respirion Pharmaceuticals Pty Ltd","startDate":"2024-04-01","conditions":"Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa","enrollment":72},{"nctId":"NCT05453578","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-10-03","conditions":"Bacterial Disease Carrier, Cystic Fibrosis","enrollment":72},{"nctId":"NCT02649751","phase":"PHASE2","title":"Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","status":"TERMINATED","sponsor":"University Hospital, Brest","startDate":"2016-02-22","conditions":"Cystic Fibrosis","enrollment":49},{"nctId":"NCT07280598","phase":"PHASE1","title":"Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-12-31","conditions":"CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection, E Coli Infections","enrollment":30},{"nctId":"NCT06548841","phase":"","title":"Development and Validation of (Bio)Sensors for the Identification of Pathogens","status":"COMPLETED","sponsor":"University of Bologna","startDate":"2024-05-30","conditions":"Infections, Infection, Bacterial, Infection Viral","enrollment":149},{"nctId":"NCT04292054","phase":"PHASE3","title":"Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-11","conditions":"Burns Surgery","enrollment":506},{"nctId":"NCT06159725","phase":"PHASE1, PHASE2","title":"A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis","status":"COMPLETED","sponsor":"Clarametyx Biosciences, Inc.","startDate":"2024-06-24","conditions":"Persistent Infection, Cystic Fibrosis","enrollment":43},{"nctId":"NCT04335383","phase":"","title":"Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies","status":"RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2020-10-05","conditions":"Pseudomonas Aeruginosa, Multi-antibiotic Resistance","enrollment":30},{"nctId":"NCT05632315","phase":"PHASE2","title":"PMT for MDRO Decolonization","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-08-19","conditions":"Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections, Pseudomonas Aeruginosa","enrollment":150},{"nctId":"NCT06950892","phase":"","title":"Remote Sputum Collection in Cystic Fibrosis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-01-15","conditions":"Cystic Fibrosis, Infections","enrollment":150},{"nctId":"NCT04970225","phase":"NA","title":"Cystic Fibrosis Blood Neutrophils","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-08","conditions":"Cystic Fibrosis","enrollment":47},{"nctId":"NCT06986512","phase":"","title":"Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Rapid Detection, Pseudomonas Aeruginosa Infection","enrollment":100},{"nctId":"NCT06998043","phase":"PHASE2","title":"Study With Phage for CF Subjects With Pseudomonas Lung Infection","status":"RECRUITING","sponsor":"BiomX Ltd","startDate":"2025-07-02","conditions":"Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)","enrollment":63},{"nctId":"NCT05010577","phase":"PHASE1, PHASE2","title":"Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection","status":"COMPLETED","sponsor":"BiomX, Inc.","startDate":"2022-06-21","conditions":"Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis","enrollment":43},{"nctId":"NCT06368804","phase":"PHASE2","title":"Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2024-09-15","conditions":"Bronchiectasis","enrollment":196},{"nctId":"NCT07056881","phase":"","title":"Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa","status":"RECRUITING","sponsor":"Centre Hospitalier de Saint-Denis","startDate":"2025-04-11","conditions":"Osteomyelitis, Pseudomonas Infections, Pseudomonas Aeruginosa","enrollment":300},{"nctId":"NCT03638830","phase":"PHASE2","title":"Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa","status":"COMPLETED","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2018-10-17","conditions":"Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa, Pseudomonas Aeruginosa, Pseudomonas Infections","enrollment":777},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT06992102","phase":"","title":"Clinical Study on the Treatment of Lower Respiratory Tract Infection With Pseudomonas Aeruginosa by Ceftazidime and Avibatam","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"MDRPA","enrollment":500},{"nctId":"NCT05422144","phase":"NA","title":"Cleanser for Acute Wounds","status":"WITHDRAWN","sponsor":"Rochal Industries LLC","startDate":"2024-01-01","conditions":"Acute Wound","enrollment":""},{"nctId":"NCT06811727","phase":"PHASE4","title":"CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients","status":"NOT_YET_RECRUITING","sponsor":"Ivan Šitum, MD","startDate":"2025-05-01","conditions":"Severe Infection","enrollment":140},{"nctId":"NCT06738771","phase":"","title":"Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa","status":"RECRUITING","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2025-03-11","conditions":"Pseudomonas Infections, Pseudomonas Aeruginosa, Prognosis","enrollment":600},{"nctId":"NCT06760273","phase":"","title":"Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-10-16","conditions":"Bronchiectasis Adult","enrollment":364},{"nctId":"NCT05017766","phase":"","title":"NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-12-03","conditions":"Antimicrobial Resistance (AMR)","enrollment":8000},{"nctId":"NCT06798168","phase":"","title":"Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa","status":"AVAILABLE","sponsor":"Ottawa Hospital Research Institute","startDate":"","conditions":"Joint Infection","enrollment":""},{"nctId":"NCT03494959","phase":"PHASE2","title":"Pentaglobin in CRE and PA Neutropenic Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","startDate":"2019-12-06","conditions":"Septic Shock","enrollment":120},{"nctId":"NCT06093191","phase":"PHASE4","title":"Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2023-09-25","conditions":"Bronchiectasis Adult, Pseudomonas Aeruginosa Infection","enrollment":364},{"nctId":"NCT06044272","phase":"","title":"Antimicrobial Resistance in Hospitals From Meta, Colombia","status":"COMPLETED","sponsor":"Hospital Departamental de Villavicencio","startDate":"2023-09-01","conditions":"Increased Drug Resistance","enrollment":10000},{"nctId":"NCT02038803","phase":"","title":"Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2013-10-10","conditions":"Cystic Fibrosis","enrollment":5},{"nctId":"NCT03581370","phase":"PHASE3","title":"Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2018-09-20","conditions":"Ventilator-associated Pneumonia","enrollment":80},{"nctId":"NCT00700050","phase":"","title":"Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2008-04","conditions":"Cystic Fibrosis","enrollment":28},{"nctId":"NCT06422533","phase":"NA","title":"Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients","status":"RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2023-11-07","conditions":"Hematologic Neoplasms, Neutropenia","enrollment":226},{"nctId":"NCT06441708","phase":"","title":"Neutrophil Extracellular Traps (NETs) Mediated Killing of Carbapenem-resistant Pseudomonas Aeruginosa.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-06-01","conditions":"Neutrophil Extracellular Traps Formation","enrollment":50},{"nctId":"NCT02295566","phase":"PHASE2","title":"RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2011-05","conditions":"Cystic Fibrosis","enrollment":12},{"nctId":"NCT06417593","phase":"","title":"Phenotypic and Genotypic Characteristics of Pseudomonas Aeruginosa Isolates in Sohag University Hospitals","status":"RECRUITING","sponsor":"Sohag University","startDate":"2024-04-01","conditions":"Pseudomonas Aeruginosa Infection","enrollment":100},{"nctId":"NCT06141837","phase":"","title":"Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at CHRU of Nancy (Pyo-COVID-3)","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2023-12-01","conditions":"Pseudomonas Aeruginosa, COVID-19","enrollment":51},{"nctId":"NCT06370299","phase":"","title":"Screening of Multidrug Resistant Bacteria, and the Clinical Implication for the Patient","status":"UNKNOWN","sponsor":"Region Skane","startDate":"2024-06-01","conditions":"Multi-antibiotic Resistance","enrollment":10000},{"nctId":"NCT06319235","phase":"PHASE1, PHASE2","title":"Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®","status":"RECRUITING","sponsor":"MB PHARMA s.r.o.","startDate":"2023-10-27","conditions":"Surgical Site Infection, Staphylococcus Aureus Infection, Pseudomonas Aeruginosa Infection","enrollment":52},{"nctId":"NCT05979545","phase":"PHASE4","title":"EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2023-12-12","conditions":"Blood Stream Infections, Ventilator Associated Pneumonia, Healthcare Associated Infection","enrollment":1900},{"nctId":"NCT06238856","phase":"PHASE1","title":"Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2004-05-12","conditions":"Cystic Fibrosis","enrollment":18},{"nctId":"NCT04596319","phase":"PHASE1, PHASE2","title":"Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis","status":"COMPLETED","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"2020-12-22","conditions":"Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas","enrollment":29},{"nctId":"NCT01303068","phase":"NA","title":"Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2012-08-15","conditions":"Cystic Fibrosis","enrollment":12},{"nctId":"NCT03044223","phase":"","title":"Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2014-08","conditions":"Pseudomonas Infections, Pseudomonas Septicemia, Pseudomonas; Pneumonia","enrollment":100},{"nctId":"NCT03460704","phase":"PHASE3","title":"Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.","status":"TERMINATED","sponsor":"Zambon SpA","startDate":"2018-01-29","conditions":"Non Cystic Fibrosis Bronchiectasis","enrollment":287},{"nctId":"NCT04735952","phase":"","title":"Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath)","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2019-05-03","conditions":"Cystic Fibrosis","enrollment":300},{"nctId":"NCT01090908","phase":"","title":"Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa","status":"WITHDRAWN","sponsor":"Aradigm Corporation","startDate":"2010-09","conditions":"Cystic Fibrosis","enrollment":""},{"nctId":"NCT04684641","phase":"PHASE1, PHASE2","title":"CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-03-29","conditions":"Cystic Fibrosis","enrollment":8},{"nctId":"NCT03093974","phase":"PHASE3","title":"Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2017-06-06","conditions":"Non Cystic Fibrosis Bronchiectasis","enrollment":377},{"nctId":"NCT05975151","phase":"PHASE2","title":"Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-10-01","conditions":"Bladder Cancer","enrollment":63},{"nctId":"NCT04376268","phase":"PHASE4","title":"Comparison of the Efficacy of Boric Acid Mouthwashes in Different Concentrations","status":"UNKNOWN","sponsor":"Yuzuncu Yil University","startDate":"2019-01-15","conditions":"Impacted Third Molar Tooth","enrollment":80},{"nctId":"NCT05902299","phase":"","title":"Evaluation of the Impact of the Modification of Antibiotic Susceptibility Testing on Antibiotic Prescriptions","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2023-05-15","conditions":"Antibiotic Resistant Infection","enrollment":199},{"nctId":"NCT05880069","phase":"","title":"Clinical Outcomes in Patients With Infection by Resistant Microorganism","status":"UNKNOWN","sponsor":"Hospital Universitario Virgen Macarena","startDate":"2022-10-01","conditions":"Pneumonia, Bloodstream Infection, Urinary Tract Infections","enrollment":5000},{"nctId":"NCT03262142","phase":"PHASE4","title":"Targeted AntiBiotics for Chronic Pulmonary Diseases","status":"TERMINATED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2018-01-10","conditions":"COPD, Respiratory Tract Infections, Pseudomonas Aeruginosa","enrollment":51},{"nctId":"NCT03439124","phase":"PHASE3","title":"Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2017-11-27","conditions":"Community-acquired Pneumonia (CAP), Hospital-acquired Pneumonia (HAP)","enrollment":138},{"nctId":"NCT03963297","phase":"","title":"Multicenter Evaluation of the Susceptibility of Enterobacteriaceae and Pseudomonas Aeruginosa to Ceftolozane/Tazobactam Combination","status":"COMPLETED","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2019-03-01","conditions":"Antibiotic Resistant Strain","enrollment":747},{"nctId":"NCT05642767","phase":"","title":"Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas Aeruginosa","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-12-01","conditions":"Pseudomonas Aeruginosa","enrollment":75},{"nctId":"NCT03218917","phase":"PHASE2","title":"Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2017-10-31","conditions":"Non-Cystic Fibrosis Bronchiectasis","enrollment":256},{"nctId":"NCT03669614","phase":"PHASE1, PHASE2","title":"SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects","status":"UNKNOWN","sponsor":"Aridis Pharmaceuticals, Inc.","startDate":"2018-12-07","conditions":"Cystic Fibrosis","enrollment":102},{"nctId":"NCT03646227","phase":"","title":"Multi-Drug Resistant Organism Network","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-06-16","conditions":"Infections Resistant to Multiple Drugs, Bacterial Infections","enrollment":6496},{"nctId":"NCT04927806","phase":"NA","title":"The Effectiveness of Antimicrobial Breathing System on the Presence of Multidrug-resistant Organisms","status":"COMPLETED","sponsor":"Fu Jen Catholic University","startDate":"2021-11-01","conditions":"Bacterial Contamination","enrollment":24},{"nctId":"NCT05675592","phase":"","title":"Trikafta/Kaftrio and Pseudomonas Aeruginosa","status":"UNKNOWN","sponsor":"Ospedale San Raffaele","startDate":"2022-02-22","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT01745796","phase":"","title":"Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2013-07-03","conditions":"Pseudomonas Aeruginosa, Ventilation Acquired Pneumonia","enrollment":77},{"nctId":"NCT05604469","phase":"","title":"The Role of Skin Microbiota in Hepatic or Renal Pruritus","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2022-10-01","conditions":"Renal Failure, Hepatic Failure, Pruritus","enrollment":60},{"nctId":"NCT02880111","phase":"","title":"Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2016-03-23","conditions":"Malignant Brain Tumor","enrollment":1},{"nctId":"NCT02458807","phase":"","title":"The SENSOR Study: A Mixed-methods Study of SElf-management Checks to Predict exacerbatioNs of Pseudomonas Aeruginosa in Patients With Long-term reSpiratORy Conditions","status":"COMPLETED","sponsor":"Portsmouth Hospitals NHS Trust","startDate":"2014-08-18","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis","enrollment":43},{"nctId":"NCT03219164","phase":"PHASE3","title":"Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2017-11-28","conditions":"Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis","enrollment":149},{"nctId":"NCT00027183","phase":"","title":"Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1998-03-17","conditions":"Pseudomonas Infection, Cystic Fibrosis","enrollment":134},{"nctId":"NCT03008746","phase":"NA","title":"Pulmonary Microbiota in Patients With Chronic Obstructive Pulmonary Disease Colonized With P. Aeruginosa Resistant to Imipenem","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2017-01-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":58},{"nctId":"NCT03418272","phase":"","title":"Cultures in PICU Patients Compared to Healthy Children","status":"WITHDRAWN","sponsor":"State University of New York at Buffalo","startDate":"2023-02","conditions":"Ventilator Associated Pneumonia, Pneumonia, Bacterial","enrollment":""},{"nctId":"NCT02449031","phase":"","title":"Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-05-05","conditions":"Pseudomonas Aeruginosa in Cystic Fibrosis","enrollment":409},{"nctId":"NCT03027609","phase":"PHASE2","title":"Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia","status":"COMPLETED","sponsor":"Aridis Pharmaceuticals, Inc.","startDate":"2017-03-29","conditions":"Pseudomonas Aeruginosa Pneumonia","enrollment":158},{"nctId":"NCT05285046","phase":"","title":"Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2022-04-01","conditions":"Bacterial Infections, Antibiotic Resistant Infection","enrollment":250},{"nctId":"NCT05251584","phase":"NA","title":"Effects of Topical Gentamicin on the Prevention of Peritoneal Dialysis Related Infection","status":"UNKNOWN","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2021-12-01","conditions":"Peritoneal Dialysis-related Infection","enrollment":60},{"nctId":"NCT01694069","phase":"PHASE4","title":"Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2012-09","conditions":"Cystic Fibrosis","enrollment":6},{"nctId":"NCT04323475","phase":"PHASE1","title":"Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients","status":"UNKNOWN","sponsor":"Precisio Biotix Therapeutics, Inc.","startDate":"2022-01","conditions":"Wound Infection","enrollment":12},{"nctId":"NCT04636554","phase":"","title":"Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia","status":"NO_LONGER_AVAILABLE","sponsor":"Adaptive Phage Therapeutics, Inc.","startDate":"","conditions":"Covid19, Bacteremia, Septicemia","enrollment":""},{"nctId":"NCT04815798","phase":"PHASE1, PHASE2","title":"Phage Therapy for the Prevention and Treatment of Pressure Ulcers.","status":"UNKNOWN","sponsor":"Precisio Biotix Therapeutics, Inc.","startDate":"2022-01","conditions":"Pressure Ulcer","enrollment":69},{"nctId":"NCT02634411","phase":"NA","title":"Impact of the Duration of Antibiotics on Clinical Events in Patients With Pseudomonas Aeruginosa Ventilator-associated Pneumonia (iDIAPASON)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-06-03","conditions":"Ventilator-Associated Pneumonia","enrollment":190},{"nctId":"NCT01359891","phase":"","title":"Clinical Evaluation of Novel Biomarkers in Patients With Septicemia","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2010-11","conditions":"Sepsis, Bacteremia, Fungemia","enrollment":750},{"nctId":"NCT03158116","phase":"PHASE4","title":"The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas","status":"TERMINATED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2017-07-01","conditions":"Tracheostomy Infection","enrollment":5},{"nctId":"NCT00043225","phase":"","title":"The Role of Bacteria and Genetic Variations in Cystic Fibrosis","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2001-06-20","conditions":"Psuedomas Infection, Cystic Fibrosis","enrollment":76}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":80612,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pseudomonas aeruginosa","genericName":"Pseudomonas aeruginosa","companyName":"Qilu Hospital of Shandong University","companyId":"qilu-hospital-of-shandong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pseudomonas aeruginosa is a broad-spectrum antibiotic that targets bacterial cell wall synthesis. Used for Pneumonia, Urinary tract infections, Skin and soft tissue infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}